Cellectar Biosciences, Inc. (CLRB)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.18
- As of
Kresmion compiles this page from CLRB's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Cellectar Biosciences, Inc. (CLRB): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-13.
See the full CLRB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CLRB on one page. Preview it with sample data, then open it live with a free account.
Preview the CLRB dossierActive signals for CLRB
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 15.6%, EPS $-0.57 vs $-0.493 estimate
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 14.8% - EPS $-3.39 vs $-3.978 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 45.3% - EPS $-1.41 vs $-2.578 estimate
- mediumEARNINGS_BEAT
Beat consensus by 14.8% - EPS $-3.39 vs $-3.978 estimate
- mediumEARNINGS_BEAT
Beat consensus by 45.3% - EPS $-1.41 vs $-2.578 estimate
FREE, NO ACCOUNT
Every signal on CLRB, as it fires
You are seeing 5 of 7 signals recorded on CLRB since 2026-05-31.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, CLRB
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
CLRB against its peers
CLRB's return on equity of -255.2% ranks in the 31st percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | CLRB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 1.0M | n/a | 13 |
| Operating margin | n/a | -986.6% | n/a | 11 |
| Net margin | n/a | -984.6% | n/a | 11 |
| Return on equity | -255.2% | -114.3% | 31 | 17 |
| 1 year | -76.3% | -44.3% | 23 | 14 |
Peers (20): CYCN, ALLR, ICU, TVRD, KTTA, DARE, BCDA, NCEL, PTN, LPCN, INTI, MRKR, LTRN, INAB, DYAI, CKDXF, LSTA, HIND, SYBX, AEON. Left out: FNCHQ (period gap), ZIVO (period gap), CTXR (no annual filing), HOOK (period gap), RADX (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (CLRB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CLRB on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CLRB for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.